Structural characterization of x2 glycosphingolipid, its extended form, and its sialosyl derivatives: accumulation associated with the rare blood group p phenotype.
Structural characterization of x2 glycosphingolipid, its extended form, and its sialosyl derivatives: accumulation associated with the rare blood group p phenotype.
复制标题
x2 鞘糖脂、其延伸形式及其唾液酸衍生物的结构特征：与稀有血型 p 表型相关的积累。
DOI：
10.1021/bi00143a022
复制
发表时间：
1992
期刊：
影响因子：
2.9
通讯作者：
Clausen,H
中科院分区：
文献类型：
--
作者：
Thorn,JJ;Levery,SB;Salyan,ME;Stroud,MR;Cedergren,B;Nilsson,B;Hakomori,S;Clausen,H
生物膜研究所，201 Elliott Avenue West，西雅图，华盛顿98199，华盛顿大学病理生物学系，西雅图，华盛顿，大学医院口腔医学和口腔外科系，哥本哈根，丹麦，哥本哈根大学健康科学学院牙科学系口腔病理学和口腔医学系以及口腔诊断系，丹麦，和Bloodcentral，Umea，瑞典接收于1992年1月21日;修订的Mandarin pt接收于1992年4月28日摘要：已经提出，x2鞘糖脂（GSL）可以为在p血型个体中发现的P样抗原活性提供结构基础[Kannagi R.，Fukuda，M. N.，Hakomori，S.（1982）J.Biol.Chem.257，4438]。x2和唾液酸基-x2 GSL的结构已通过+ FAB-MS、GC-MS甲基化分析和1H-NMR明确证实，如下所示。我们已经建立了特异于GalNAc/31-* 3Gal/31-> 4G 1cNAc/31-* 3Gal/31-> 4Glc/31-> ICer唾液酸基-x2神经元2-> 3GalNAc/31-* 3Gal/31-* 4GlcNAc/31-* 3Gal/31-> 4Glc/31-> 1Cer单克隆抗体（TH 2），x2 GSL的末端三糖。应用单抗TH_2进行TLC免疫印迹和化学分析表明：（i）存在具有相同x_2末端结构的延伸型GSL：（ii）血细胞和各种组织包括癌中的x_2、唾液酸-x_2和延伸x_2的化学量几乎相同;（iii）在罕见p血型个体的血液样本中发现相当大量的x2和x2衍生结构。x2及其衍生物在p个体的血细胞中的积累与这些GSL在正常人红细胞和组织中作为极少量组分的出现相反，并且它们可能是p血型个体中报道的P样活性的原因[Naiki，M.，& Marcus，D. M.等（1977）J. Immunol.119，537]。
The Biomembrane Institute, 201 Elliott Avenue West, Seattle, Washington 98199, Department of Pathobiology, University of Washington, Seattle, Washington, Department of Oral Medicine and Oral Surgery, University Hospital, Copenhagen, Denmark, Department of Oral Pathology and Oral Medicine and Department of Oral Diagnosis, School of Dentistry, Faculty of Health Sciences, University of Copenhagen, Denmark, and Bloodcentral, Umea, Sweden Received January 21, 1992; Revised Manuscript Received April 28, 1992 abstract: It has been suggested that the x2 glycosphingolipid (GSL) could offer a structural basis for a P-like antigen activity found in blood group p individuals [Kannagi R., Fukuda, M. N., Hakomori, S.(1982) J. Biol. Chem. 257, 4438]. The structures of the x2 and sialosyl-x2 GSLs have been confirmed unequivocally as shown below by+ FAB-MS, methylation analysis by GC-MS, and'H-NMR. We have established a x2 GalNAc/3 l-* 3Gal/3 1-> 4G1cNAc/3 l—3Gal/3 l-» 4Glc/31-> ICer sialosyl-x2 NeuAca2-» 3GalNAc/3 l-* 3Gal/3 l-* 4GlcNAc/3 l-* 3Gal/3 l-> 4Glc/3 l-> lCer monoclonal antibody (TH2) specific for the GalNAc/31—*-3Gal/31—*-4GlcNAc epitope, the terminal tri-saccharide of x2 GSL. Application of MAb TH2 on TLC immunoblotting together with chemicalanalysis indicates the following points of interest:(i) the existence of extended type GSLs having the same x2 terminal structure;(ii) the chemical quantities of x2, sialosyl-x2, and extended x2 found in blood cells and in various tissues including carcinomas being nearly the same;(iii) considerably larger quantities of x2 and x2-derived structures found in blood samples of rare blood group p individuals. The accumulation of x2 and its derivatives in bloodcells of p individuals is in contrast to the occurrence of these GSLs as extreme minor components in normal human red blood cells and tissues, and they may be responsible for the reported P-like activity in blood group p individuals [Naiki, M., & Marcus, D. M.(1977) J. Immunol. 119, 537].